Table.
Baseline characteristics of patients
| All randomised patients (N=752) | CMR and x-ray angiography assessable (N=676) | CMR, SPECT, and x-ray angiography assessable (CMR before SPECT; N=316) | CMR, SPECT, and X-ray angiography assessable (SPECT before CMR; N=312) | ||
|---|---|---|---|---|---|
| Age (years) | 60·2 (9·7) | 60·3 (9·5) | 60·8 (9·6) | 59·9 (9·2) | |
| Men | 471 (63%) | 421 (62%) | 193 (61%) | 200 (64%) | |
| Body-mass index (kg/m2) | 29·2 (4·4) | 29·0 (4·3) | 29·1 (4·4) | 28·9 (4·2) | |
| Ethnic origin | |||||
| White | 711 (95%) | 643 (95%) | 295 (93%) | 302 (97%) | |
| Black | 6 (1%) | 5 (1%) | 1 (<1%) | 3 (1%) | |
| Asian | 30 (4%) | 24 (4%) | 17 (5%) | 6 (2%) | |
| Other | 5 (1%) | 4 (1%) | 3 (1%) | 1 (<1%) | |
| Smoking status | |||||
| Never smoked | 257 (34%) | 236 (35%) | 112 (35%) | 112 (36%) | |
| Ex-smoker | 350 (47%) | 315 (47%) | 150 (47%) | 144 (46%) | |
| Current smoker | 145 (19%) | 125 (18%) | 54 (17%) | 56 (18%) | |
| Systolic blood pressure (mm Hg) | 137·9 (20·7) | 138·1 (20·9) | 136·9 (21·5) | 138·6 (20·4) | |
| Diastolic blood pressure (mm Hg) | 79·0 (11·3) | 79·0 (11·3) | 78·5 (11·0) | 79·2 (11·6) | |
| Previous hospital admission for AMI or ACS | 60 (8%) | 54 (8%) | 31 (10%) | 21 (7%) | |
| Previous PCI | 38 (5%) | 37 (5%) | 20 (6%) | 15 (5%) | |
| Hypertension | 394 (52%) | 347 (51%) | 160 (51%) | 154 (49%) | |
| Diabetes mellitus | 96 (13%) | 85 (13%) | 49 (16%) | 34 (11%) | |
| Type 1 | 4/96 (4%) | 4 (5%) | 3 (6%) | 1 (3%) | |
| Type 2 | 92/96 (96%) | 81 (95%) | 46 (94%) | 33 (97%) | |
| Family history of premature heart disease | |||||
| Yes | 430 (57%) | 392 (58%) | 178 (56%) | 187 (60%) | |
| No | 268 (36%) | 237 (35%) | 118 (37%) | 99 (32%) | |
| Unknown | 54 (7%) | 47 (7%) | 20 (6%) | 26 (8%) | |
| Total cholesterol (mmol/L) | 5·2 (1·2) | 5·2 (1·2) | 5·1 (1·2) | 5·2 (1·2) | |
| Simplified Framingham risk score* | 13·7 (3·6; n=692) | 13·6 (3·6; n=622) | 13·7 (3·7; n=285) | 13·5 (3·5; n=291) | |
| Medication | |||||
| Aspirin or clopidogrel | 454 (60%) | 404 (60%) | 189 (60%) | 184 (59%) | |
| Statin | 336 (49%) | 301 (45%) | 151 (48%) | 129 (41%) | |
| ACEi or A2 receptor blockers | 258 (38%) | 229 (34%) | 112 (35%) | 96 (31%) | |
| β-blocker | 235 (34%) | 203 (30%) | 93 (29%) | 93 (30%) | |
| Patients undergoing x-ray angiography† | n=726 | n=676 | n=316 | n=312 | |
| Any significant stenosis | 282 (39%) | 266 (39%) | 125 (40%) | 123 (39%) | |
| Triple-vessel disease | 45 (6%) | 40 (6%) | 21 (7%) | 16 (5%) | |
| Double-vessel disease | 88 (12%) | 83 (12%) | 35 (11%) | 45 (14%) | |
| Single-vessel disease | 149 (21%) | 143 (21%) | 69 (22%) | 62 (20%) | |
| LMS disease | 23 (3%) | 22 (3%) | 12 (4%) | 9 (3%) | |
| LAD disease | 183 (25%) | 169 (25%) | 79 (25%) | 79 (25%) | |
| LCX disease | 133 (18%) | 126 (19%) | 55 (17%) | 65 (21%) | |
| RCA disease | 110 (15%) | 105 (16%) | 51 (16%) | 42 (13%) | |
Data are mean (SD) or n (%) unless otherwise stated.
*
Percentage risk of an event in the absence of chest pain over 10 years; patients with previous coronary heart disease had no risk score calculated; those older than age 75 years were assumed to be 75 years.27
†
Numbers of patients undergoing x-ray angiography includes those with completed or partly completed non-invasive test results. AMI=acute myocardial infarction. ACS=acute coronary syndrome. PCI=percutaneous coronary intervention. ACEi=angiotensin converting enzyme inhibitor. A2=angiotensin 2. LMS=left main stem. LAD=left anterior descending. LCx=left circumflex. RCA=right coronary artery.